Safety Study of BIIB033 in Subjects With Multiple Sclerosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic profile of two intravenous infusions of BIIB033 (anti-LINGO-1).
Approximately 42 MS subjects are planned to be enrolled in the study in 7 separate groups (i.e., 6 subjects per group). Each subsequent group will be administered a higher dose of BIIB033. Before a higher dose group is allowed to start, a Drug Safety Review Committee will review all safety data from previous groups enrolled, as well as data from another study where BIIB033 is being administered to healthy volunteers (215HV101).
For detailed information on the outcome measures and the inclusion and exclusion criteria please see entry on clinicaltrials-dot-gov.
“Exciting or not?”
CoI: I have previously consulted for Biogen-Idec the company who is developing this drug.